Renting Rubin : AstraZeneca III – The $400 Billion Adverse Reaction
The first AstraZeneca instalment examined its reputation-management placebo. Part II followed the company’s “patients first” rhetoric to the public purse. […]
The first AstraZeneca instalment examined its reputation-management placebo. Part II followed the company’s “patients first” rhetoric to the public purse. […]
Horsfield Menzies trainee solicitor Marcia Sumbe wrote an article telling employers exactly what to do when misconduct may arise from
Horsfield Menzies has done something unusually useful for an adversary: it has published the ruler. Partner Laura McLellan writes about
Thompson’s appeal against Cummins had already been rejected at the initial sift. By the time it reached HHJ Tayler under
Today’s Chambers Chatter stays at 4-5 Gray’s Inn Square, where Wendy Miller operates as an associate member. Miller represented Cummins
So welcome back to Shareholder Spotlight. A Sunday Special, no less. The ABN AMRO Cummins stake gives us 46,273 fresh
The Barclays Qatar capital raising sold independence from government money. Meanwhile, £322 million sat behind advisory agreements the FCA later
TCAP found the Cummins case studies archive, pulled more than 200 customers out of its 464-entry corporate filing cabinet and
This one started with a joke. I searched DuckDuckGo for “Cepac disability”, screenshotted the result and ribbed Cepac on X